Kopran
- Market cap
- ₹ 1,179 Cr.
- P/E
- 47.8x
- P/B
- 2.38x
- 52-week range
- 107 – 295.83
- ROE
- 5%
- ROCE
- 7%
- Dividend yield
- 1.2%
- Debt / equity
- 0.29
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Kopran against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)47.8 against a typical 33.2: pricier than most peers (1st = cheapest).155th of 220
- Sales growth+13.9% against a typical +15.6% from a year earlier.106th of 197
- Profit growth−10.1% against a typical +18.9% from a year earlier.109th of 160
- Share price, 3 months+29.8% against a typical −1.8%.22nd of 200
- Size₹ 1,179 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).83rd of 199
Latest announcements
Exchange filings and their impact on the company.
- EU inspection at Khopoli ends with no critical findings, keeping EU formulation business intact.
Kopran said the EU GMP inspection at its Khopoli formulation plant from September 18-23, 2026 closed with no critical or data-integrity observations, with one major and some minor observations. The company will submit its compliance response within a fortnight. The outcome preserves EU market access for the site and should lead to formal closure if the response is accepted.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB+/Watch Developing | Watch: Developing | 18 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 18 Sep 2026 | Reaffirmed | Crisil BBB+/Watch Developing | — | CRISIL | ₹ 69.31 Cr. | |
| 22 Jun 2026 | Reaffirmed | Crisil BBB+/Watch Developing | — | CRISIL | ₹ 69.31 Cr. | |
| 24 Mar 2026 | Reaffirmed | Crisil BBB+/Watch Developing | — | CRISIL | ₹ 69.31 Cr. | |
| 24 Dec 2025 | Reaffirmed | Crisil BBB+/Watch Developing | — | CRISIL | ₹ 69.31 Cr. | |
| 26 Sep 2025 | Reaffirmed | Crisil BBB+/Watch Developing | — | CRISIL | ₹ 69.31 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 7 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 19 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 22 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 29 Jul 2025 | Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2025 |
| 15 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 159 | 186 | 139 | 152 | 166 | 172 | 135 | 118 | 194 | 234 | 154 |
| Expenses | 130 | 135 | 164 | 121 | 137 | 146 | 155 | 121 | 123 | 177 | 201 | 138 |
| Operating Profit | 23 | 24 | 22 | 18 | 15 | 20 | 17 | 14 | −5 | 18 | 33 | 16 |
| OPM % | 15% | 14.8% | 11.7% | 13% | 9.7% | 11.9% | 9.9% | 10.5% | −4.5% | 9.1% | 14.1% | 10.3% |
| Other Income | 0 | 2 | 10 | 3 | 1 | 0 | 3 | 3 | 0 | 0 | 0 | 2 |
| Interest | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 3 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 |
| Profit before tax | 18 | 21 | 25 | 15 | 10 | 14 | 14 | 10 | −12 | 11 | 25 | 9 |
| Tax % | 24.6% | 23% | 26% | 24.7% | 23.4% | 25% | 29.4% | 24.7% | −14.6% | 13% | 25.6% | 23.8% |
| Net Profit | 14 | 16 | 19 | 11 | 7 | 10 | 10 | 7 | −10 | 9 | 19 | 7 |
| EPS in Rs | 2.86 | 3.28 | 3.86 | 2.3 | 1.53 | 2.16 | 2.01 | 1.54 | −2.06 | 1.94 | 3.91 | 1.39 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 9%
- 5 Years
- 7%
- 3 Years
- 7%
- TTM
- 12%
- 10 Years
- 8%
- 5 Years
- −16%
- 3 Years
- −2%
- TTM
- −28%
- 10 Years
- 15%
- 5 Years
- 0%
- 3 Years
- 3%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Kopran | ₹ 253.40 | ₹ 1,179 Cr. | 47.8x | 2.4x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Surendra Somani
- Executive Vice Chairman of the Board
- Basant K. Soni
- Chief Financial Officer
- Vijay L. Thange
- Chief Technical Officer
- Sunil Radheyshyam Sodhani
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.